Open AccessAnti-inflammatory drugs with therapeutic effects and drug regulators
Author(s) -
Prateek Paul,
Manvi
Publication year - 2021
Publication title -
himalayan journal of health sciences
Language(s) - English
Resource type - Journals
ISSN - 2582-0737
DOI - 10.22270/hjhs.v6i3.106
Subject(s) - cyclooxygenase , aspirin , pharmacology , anti inflammatory , drug , medicine , inflammation , enzyme , celecoxib , cancer , prostaglandin , isozyme , chemistry , biochemistry
For prostaglandin production, the enzyme cyclooxygenase (COX) is required. The two COX isoforms are constitutive COX-1 (which is responsible for physiological functions) and inducible COX-2 (involved in inflammation). COX inhibition explains both the medicinal (inhibition of COX-2) and negative effects (inhibition of COX-1) effects of non-steroidal anti-inflammatory medicines (NSAIDs). Nonsteroidal anti-inflammatory medicines (NSAIDs) act by blocking the enzyme cyclooxygenase (COX), which produces prostaglandins (PGs). To a greater or lesser extent, they share similar side effects, such as stomach and renal toxicity. According to a recent study, there are at least two COX isoenzymes. COX-1 is a naturally occurring enzyme that creates prostaglandins (PGs), which protect the stomach and kidneys. Aspirin's well-known anti-cancer impact could also be related to its influence on COX-2, which is expressed in this condition. As a result, selective COX-2 inhibitors may have new therapeutic potential as anticancer drugs, as well as in preventing premature labor and maybe reducing the progression of Alzheimer's disease.